367 related articles for article (PubMed ID: 30561737)
1. Evaluation of Possible Proarrhythmic Potency: Comparison of the Effect of Dofetilide, Cisapride, Sotalol, Terfenadine, and Verapamil on hERG and Native IKr Currents and on Cardiac Action Potential.
Orvos P; Kohajda Z; Szlovák J; Gazdag P; Árpádffy-Lovas T; Tóth D; Geramipour A; Tálosi L; Jost N; Varró A; Virág L
Toxicol Sci; 2019 Apr; 168(2):365-380. PubMed ID: 30561737
[TBL] [Abstract][Full Text] [Related]
2. Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel.
Davie C; Pierre-Valentin J; Pollard C; Standen N; Mitcheson J; Alexander P; Thong B
J Cardiovasc Electrophysiol; 2004 Nov; 15(11):1302-9. PubMed ID: 15574182
[TBL] [Abstract][Full Text] [Related]
3. Human stem cell-derived cardiomyocytes detect drug-mediated changes in action potentials and ion currents.
Gibson JK; Yue Y; Bronson J; Palmer C; Numann R
J Pharmacol Toxicol Methods; 2014; 70(3):255-67. PubMed ID: 25219538
[TBL] [Abstract][Full Text] [Related]
4. A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG.
Rampe D; Roy ML; Dennis A; Brown AM
FEBS Lett; 1997 Nov; 417(1):28-32. PubMed ID: 9395068
[TBL] [Abstract][Full Text] [Related]
5. Proarrhythmic risk assessment using conventional and new in vitro assays.
Goineau S; Castagné V
Regul Toxicol Pharmacol; 2017 Aug; 88():1-11. PubMed ID: 28506844
[TBL] [Abstract][Full Text] [Related]
6. Block of HERG-carried K+ currents by the new repolarization delaying agent H 345/52.
Amos GJ; Jacobson I; Duker G; Carlsson L
J Cardiovasc Electrophysiol; 2003 Jun; 14(6):651-8. PubMed ID: 12875428
[TBL] [Abstract][Full Text] [Related]
7. Facilitation of
Furutani K; Tsumoto K; Chen IS; Handa K; Yamakawa Y; Sack JT; Kurachi Y
J Gen Physiol; 2019 Feb; 151(2):214-230. PubMed ID: 30674563
[TBL] [Abstract][Full Text] [Related]
8. Reliable identification of cardiac liability in drug discovery using automated patch clamp: Benchmarking best practices and calibration standards for improved proarrhythmic assessment.
Brinkwirth N; Takasuna K; Doi M; Becker N; Obergrussberger A; Friis S; Furukawa H; Hasegawa Y; Oka T; Ohtsuki A; Fertig N; Stoelzle-Feix S
J Pharmacol Toxicol Methods; 2020 Sep; 105():106884. PubMed ID: 32565325
[TBL] [Abstract][Full Text] [Related]
9. Investigating dynamic protocol-dependence of hERG potassium channel inhibition at 37 degrees C: Cisapride versus dofetilide.
Milnes JT; Witchel HJ; Leaney JL; Leishman DJ; Hancox JC
J Pharmacol Toxicol Methods; 2010; 61(2):178-91. PubMed ID: 20172036
[TBL] [Abstract][Full Text] [Related]
10. Comparison of guinea-pig ventricular myocytes and dog Purkinje fibres for in vitro assessment of drug-induced delayed repolarization.
Terrar DA; Wilson CM; Graham SG; Bryant SM; Heath BM
J Pharmacol Toxicol Methods; 2007; 56(2):171-85. PubMed ID: 17596973
[TBL] [Abstract][Full Text] [Related]
11. Human embryonic stem cell derived cardiac myocytes detect hERG-mediated repolarization effects, but not Nav1.5 induced depolarization delay.
Qu Y; Gao B; Fang M; Vargas HM
J Pharmacol Toxicol Methods; 2013; 68(1):74-81. PubMed ID: 23518063
[TBL] [Abstract][Full Text] [Related]
12. Restricting excessive cardiac action potential and QT prolongation: a vital role for IKs in human ventricular muscle.
Jost N; Virág L; Bitay M; Takács J; Lengyel C; Biliczki P; Nagy Z; Bogáts G; Lathrop DA; Papp JG; Varró A
Circulation; 2005 Sep; 112(10):1392-9. PubMed ID: 16129791
[TBL] [Abstract][Full Text] [Related]
13. The [3H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K+]o.
Diaz GJ; Daniell K; Leitza ST; Martin RL; Su Z; McDermott JS; Cox BF; Gintant GA
J Pharmacol Toxicol Methods; 2004; 50(3):187-99. PubMed ID: 15519905
[TBL] [Abstract][Full Text] [Related]
14. In silico screening of the impact of hERG channel kinetic abnormalities on channel block and susceptibility to acquired long QT syndrome.
Romero L; Trenor B; Yang PC; Saiz J; Clancy CE
J Mol Cell Cardiol; 2014 Jul; 72():126-37. PubMed ID: 24631769
[TBL] [Abstract][Full Text] [Related]
15. Impaired Inactivation of L-Type Ca2+ Current as a Potential Mechanism for Variable Arrhythmogenic Liability of HERG K+ Channel Blocking Drugs.
Kim JG; Sung DJ; Kim HJ; Park SW; Won KJ; Kim B; Shin HC; Kim KS; Leem CH; Zhang YH; Cho H; Bae YM
PLoS One; 2016; 11(3):e0149198. PubMed ID: 26930604
[TBL] [Abstract][Full Text] [Related]
16. Blockade of HERG and Kv1.5 by ketoconazole.
Dumaine R; Roy ML; Brown AM
J Pharmacol Exp Ther; 1998 Aug; 286(2):727-35. PubMed ID: 9694927
[TBL] [Abstract][Full Text] [Related]
17. Hydroxypropyl beta-cyclodextrins: a misleading vehicle for the in vitro hERG current assay.
Mikhail A; Fischer C; Patel A; Long MA; Limberis JT; Martin RL; Cox BF; Gintant GA; Su Z
J Cardiovasc Pharmacol; 2007 May; 49(5):269-74. PubMed ID: 17513944
[TBL] [Abstract][Full Text] [Related]
18. Screening for acute IKr block is insufficient to detect torsades de pointes liability: role of late sodium current.
Yang T; Chun YW; Stroud DM; Mosley JD; Knollmann BC; Hong C; Roden DM
Circulation; 2014 Jul; 130(3):224-34. PubMed ID: 24895457
[TBL] [Abstract][Full Text] [Related]
19. Does terfenadine-induced ventricular tachycardia/fibrillation directly relate to its QT prolongation and Torsades de Pointes?
Lu HR; Hermans AN; Gallacher DJ
Br J Pharmacol; 2012 Jun; 166(4):1490-502. PubMed ID: 22300168
[TBL] [Abstract][Full Text] [Related]
20. Functional Impact of BeKm-1, a High-Affinity hERG Blocker, on Cardiomyocytes Derived from Human-Induced Pluripotent Stem Cells.
De Waard S; Montnach J; Ribeiro B; Nicolas S; Forest V; Charpentier F; Mangoni ME; Gaborit N; Ronjat M; Loussouarn G; Lemarchand P; De Waard M
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32998413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
